JP2020502134A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502134A5 JP2020502134A5 JP2019531809A JP2019531809A JP2020502134A5 JP 2020502134 A5 JP2020502134 A5 JP 2020502134A5 JP 2019531809 A JP2019531809 A JP 2019531809A JP 2019531809 A JP2019531809 A JP 2019531809A JP 2020502134 A5 JP2020502134 A5 JP 2020502134A5
- Authority
- JP
- Japan
- Prior art keywords
- drugs
- drug
- plasminogen
- composition according
- tissue damage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000005084 renal tissue Anatomy 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 11
- 229940079593 drug Drugs 0.000 claims 11
- 230000000451 tissue damage Effects 0.000 claims 11
- 231100000827 tissue damage Toxicity 0.000 claims 11
- 102000013566 Plasminogen Human genes 0.000 claims 9
- 108010051456 Plasminogen Proteins 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 5
- 239000002220 antihypertensive agent Substances 0.000 claims 3
- 229940127088 antihypertensive drug Drugs 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010037601 Pyelonephritis chronic Diseases 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 229940127219 anticoagulant drug Drugs 0.000 claims 2
- 239000003472 antidiabetic agent Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000006368 chronic pyelonephritis Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000002934 diuretic Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000003527 fibrinolytic agent Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000037157 Azotemia Diseases 0.000 claims 1
- 208000002330 Congenital Heart Defects Diseases 0.000 claims 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 claims 1
- 206010014418 Electrolyte imbalance Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000031814 IgA Vasculitis Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102000001938 Plasminogen Activators Human genes 0.000 claims 1
- 108010001014 Plasminogen Activators Proteins 0.000 claims 1
- 208000004732 Systemic Vasculitis Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000003276 anti-hypertensive effect Effects 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 229940121357 antivirals Drugs 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000496 cardiotonic agent Substances 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000028831 congenital heart disease Diseases 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000018914 glucose metabolism disease Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000001524 infective effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000003907 kidney function Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 108010087750 lysyl-plasminogen Proteins 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 206010062198 microangiopathy Diseases 0.000 claims 1
- 108010049112 miniplasminogen Proteins 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 229930014626 natural product Natural products 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229940127126 plasminogen activator Drugs 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000011251 protective drug Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 229940034208 thyroxine Drugs 0.000 claims 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 208000009852 uremia Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2016/110169 | 2016-12-15 | ||
| CN2016110169 | 2016-12-15 | ||
| CNPCT/CN2016/110174 | 2016-12-15 | ||
| CN2016110174 | 2016-12-15 | ||
| PCT/CN2017/089060 WO2018107700A1 (zh) | 2016-12-15 | 2017-06-19 | 一种预防和治疗病理性肾组织损伤的方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502134A JP2020502134A (ja) | 2020-01-23 |
| JP2020502134A5 true JP2020502134A5 (enExample) | 2020-07-30 |
| JP7182793B2 JP7182793B2 (ja) | 2022-12-05 |
Family
ID=62557856
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531809A Active JP7182793B2 (ja) | 2016-12-15 | 2017-06-19 | 病理学的腎組織損傷を予防及び治療するための方法 |
| JP2019531812A Active JP7242057B2 (ja) | 2016-12-15 | 2017-06-19 | 薬物性腎損傷を予防及び治療するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531812A Active JP7242057B2 (ja) | 2016-12-15 | 2017-06-19 | 薬物性腎損傷を予防及び治療するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20190328848A1 (enExample) |
| EP (2) | EP3556388A4 (enExample) |
| JP (2) | JP7182793B2 (enExample) |
| CN (2) | CN110167582A (enExample) |
| CA (2) | CA3047170A1 (enExample) |
| TW (4) | TW201822797A (enExample) |
| WO (3) | WO2018107699A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7213552B2 (ja) | 2016-12-15 | 2023-01-27 | タレンゲン インターナショナル リミテッド | 肝の繊維化を予防及び治療するための方法 |
| CA3067890A1 (en) | 2017-06-19 | 2018-12-27 | Talengen International Limited | Method for regulating and controling glp-1/glp-1r and drug |
| TWI868051B (zh) * | 2017-06-23 | 2025-01-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
| CN113456579B (zh) * | 2021-07-12 | 2023-04-25 | 南开大学 | 具有双靶点的hdac抑制剂的纳米胶束-水凝胶制剂在治疗急性肾损伤药物中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| CN87104683A (zh) * | 1986-05-15 | 1988-12-21 | 埃默里大学 | 改善血纤维蛋白溶解作用的组合物 |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| US7202066B2 (en) * | 2002-01-29 | 2007-04-10 | Carrington Laboratories, Inc. | Combination of a growth factor and a protease enzyme |
| MXPA04007585A (es) * | 2002-02-06 | 2005-09-20 | N Zyme Biotec Gmbh | Metodo para la produccion de proteinas recombinantes en microorganismos. |
| JP2006507297A (ja) * | 2002-05-13 | 2006-03-02 | チルドレンズ・ホスピタル・ロサンジェルス | ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防 |
| EP1569899B1 (en) * | 2002-12-10 | 2006-06-28 | Wyeth | Substituted 3-alkyl- and 3-arylalkyl-1h-indol-1-yl-acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| US20050250694A1 (en) * | 2003-10-10 | 2005-11-10 | Ma Jian-Xing | Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same |
| WO2006023864A1 (en) * | 2004-08-23 | 2006-03-02 | Wyeth | Pyrrolo-naphthyl acids as pai-1 inhibitors |
| US8741260B2 (en) | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| CA2662101C (en) * | 2006-08-28 | 2015-07-07 | Omnio Healer Ab | Candidates against infection |
| ES2516717T3 (es) * | 2009-05-26 | 2014-10-31 | Universidad De Salamanca | Proteína activadora de GM2 en orina como marcador de fallo renal agudo o de riesgo de desarrollar fallo renal agudo |
| NZ597452A (en) * | 2009-07-10 | 2013-10-25 | Thrombogenics Nv | Variants of plasminogen and plasmin |
| CN102121023B (zh) * | 2010-12-22 | 2012-07-04 | 中山大学 | 突变型人纤溶酶原kringle5及其制备方法及应用 |
| CA2823491A1 (en) * | 2011-01-05 | 2012-07-12 | Thrombogenics Nv | Plasminogen and plasmin variants |
| CN102154253A (zh) | 2011-01-06 | 2011-08-17 | 郑州大学 | 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途 |
| CN107496899A (zh) | 2011-09-29 | 2017-12-22 | 梅约医学教育与研究基金会 | 芳族阳离子肽和使用它们的方法 |
| BR112016002753A2 (pt) * | 2013-08-13 | 2017-11-21 | Sanofi Sa | anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos |
| MX2016010852A (es) * | 2014-02-21 | 2016-10-26 | Astellas Pharma Inc | Anticuerpo anti-inhibidor de activador de plasminogeno 1 (pai-1) humano novedoso. |
-
2017
- 2017-06-19 CA CA3047170A patent/CA3047170A1/en not_active Abandoned
- 2017-06-19 EP EP17881449.7A patent/EP3556388A4/en active Pending
- 2017-06-19 WO PCT/CN2017/089059 patent/WO2018107699A1/zh not_active Ceased
- 2017-06-19 US US16/469,960 patent/US20190328848A1/en not_active Abandoned
- 2017-06-19 CN CN201780078117.3A patent/CN110167582A/zh active Pending
- 2017-06-19 WO PCT/CN2017/089060 patent/WO2018107700A1/zh not_active Ceased
- 2017-06-19 CA CA3047171A patent/CA3047171A1/en not_active Abandoned
- 2017-06-19 CN CN201780078167.1A patent/CN110366427A/zh active Pending
- 2017-06-19 TW TW106120455A patent/TW201822797A/zh unknown
- 2017-06-19 JP JP2019531809A patent/JP7182793B2/ja active Active
- 2017-06-19 JP JP2019531812A patent/JP7242057B2/ja active Active
- 2017-06-19 US US16/469,991 patent/US20190343930A1/en not_active Abandoned
- 2017-06-19 TW TW110102361A patent/TW202123962A/zh unknown
- 2017-06-19 EP EP17880935.6A patent/EP3556386A4/en active Pending
- 2017-06-19 WO PCT/CN2017/089055 patent/WO2018107695A1/zh not_active Ceased
- 2017-06-20 TW TW106120521A patent/TWI642441B/zh active
- 2017-06-20 TW TW106120523A patent/TWI661838B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Angiolillo et al. | International expert consensus on switching platelet P2Y12 receptor–inhibiting therapies | |
| Pitt et al. | Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors | |
| Wollert et al. | Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial | |
| Schächinger et al. | Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial | |
| Savelieva et al. | Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines | |
| JP2017509624A5 (enExample) | ||
| Ito | Dyslipidemia: management using optimal lipid-lowering therapy | |
| Bassand | Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents | |
| Olivera et al. | Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs | |
| JP2020511416A5 (enExample) | ||
| Kubica et al. | Rationale and Design of the Effectiveness of LowEr maintenanCe dose of TicagRelor early After myocardial infarction (ELECTRA) pilot study | |
| JP2020510628A5 (enExample) | ||
| Mathur et al. | Five-year follow-up of intracoronary autologous cell therapy in acute myocardial infarction: the REGENERATE-AMI trial | |
| Shi et al. | Tranexamic acid in on-pump coronary artery bypass grafting without clopidogrel and aspirin cessation: randomized trial and 1-year follow-up | |
| RU2018140900A (ru) | Семаглутид при сердечно-сосудистых состояниях | |
| Kang et al. | Effects of low-dose niacin on dyslipidemia and serum phosphorus in patients with chronic kidney disease | |
| Albrecht et al. | Pharmacokinetics of tecarfarin and warfarin in patients with severe chronic kidney disease | |
| JP2020502155A5 (enExample) | ||
| JP2020511413A5 (enExample) | ||
| Song et al. | Effects of dabigatran regulates no-reflow phenomenon in acute myocardial infarction mice through anti-inflammatory and anti-oxidative activities and connective tissue growth factor expression | |
| Jo et al. | High-dose atorvastatin for preventing contrast-induced nephropathy in primary percutaneous coronary intervention | |
| JP2012515165A5 (enExample) | ||
| Lee et al. | Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol intervention prevention study (LIPS) | |
| JP2015504094A5 (enExample) | ||
| RU2017129068A (ru) | Способ лечения или профилактики атеротромботических явлений у пациентов с инфарктом миокарда в анамнезе |